Clinical trial
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
NCT00134186 · Pharmacyclics LLC., Industry · Completed
Key facts
| NCT number | NCT00134186 |
|---|---|
| Title | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer |
| Official title | Phase II Trial of Motexafin Gadolinium for Treatment of Metastatic Renal Cell Carcinoma |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell, Urogenital Neoplasms, Urologic Neoplasms, Kidney Neoplasms |
| Intervention type | Drug |
| Interventions | motexafin gadolinium |
| Enrollment | 43 |
| First posted | Aug 24, 2005 |
| Last update posted | Mar 5, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: